靶向KRAS在非小细胞肺癌中的近期进展与新方法
KRAS是人癌症中最常见的RAS突变亚型,占RAS突变的85%,见于35%的肺腺癌。历史上直接或间接靶向KRAS的尝试收效甚微,尚无KRAS特异性靶向治疗获批。switch II口袋的发现促进了sotorasib和adagrasib等直接KRASG12C抑制剂的发展,在经治KRASG12C突变NSCLC中单药显示出临床活性。
要点
- KRAS占人癌症RAS突变的85%,见于35%的肺腺癌。
- 尚无KRAS特异性靶向治疗获批用于KRAS突变NSCLC患者。
- sotorasib和adagrasib在经治KRASG12C突变NSCLC中单药显示临床活性。
核心结论
- 直接KRASG12C抑制剂sotorasib和adagrasib在经治KRASG12C突变NSCLC中显示临床活性,提示新的治疗选择即将出现。
研究设计与样本
- 本文为综述,总结靶向KRAS在NSCLC中的近期进展与新方法。
主要发现
- KRAS占人癌症RAS突变的85%,存在于35%的肺腺癌中。
- 历史上直接和间接靶向KRAS的尝试收效甚微,尚无KRAS特异性靶向治疗获批。
- Ostrem、Shokat等发现KRAS活性与非活性形式表面的switch II口袋,促进了对RAS家族信号蛋白复杂相互作用的理解。
关键数值与推荐
- KRAS占人癌症RAS突变的85%,见于35%的肺腺癌。
- 在经治KRASG12C突变NSCLC患者中,sotorasib和adagrasib单药均显示临床活性。
局限性
- 耐药机制、最佳联合策略以及KRASG12C抑制剂在晚期/转移性NSCLC更早线治疗中的合适活性等问题尚待解答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rat sarcoma (RAS) is the most frequently mutated oncogene in human cancer, with Kirsten rat sarcoma (KRAS) being the most commonly mutated RAS isoform. Overall, KRAS accounts for 85% of RAS mutations observed in human cancers and is present in 35% of lung adenocarcinomas (LUADs). While the use of targeted therapies and immune checkpoint inhibitors (CPIs) has drastically changed the treatment landscape of advanced non-small-cell lung cancer (NSCLC) in recent years, historic attempts to target KRAS (both direct and indirect approaches) have had little success, and no KRAS-specific targeted therapies have been approved to date for patients in this molecular subset of NSCLC. With the discovery by Ostrem, Shokat, and colleagues of the switch II pocket on the surface of the active and inactive forms of KRAS, we now have an improved understanding of the complex interactions involved in the RAS family of signaling proteins which has led to the development of a number of promising direct KRASG12C inhibitors, such as sotorasib and adagrasib. In previously treated patients with KRASG12C-mutant NSCLC, clinical activity has been shown for both sotorasib and adagrasib monotherapy; these data suggest promising new treatment options are on the horizon. With the stage now set for a new era in the treatment of KRASG12C-mutated NSCLC, many questions remain to be answered in order to further elucidate the mechanisms of resistance, how best to use combination strategies, and if KRASG12C inhibitors will have suitable activity in earlier lines of therapy for patients with advanced/metastatic NSCLC.
引用
- Reck M, Carbone DP, Garassino M, et al. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021. PMID: 34089836. doi:10.1016/j.annonc.2021.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。